Company: AEMD
Filing Date: 2025-04-08
Form Type: PRE 14A
Source: 0001683168-25-002332
Chunk: 14

Company: AETHLON MEDICAL INC
Filing Date: 2025-04-08
Form: PRE 14A
Chunk 14
---
                                                                                                |
| (9)  | Consists of 21,238 shares subject to stock options that are currently                                                                 
 exercisable or will be exercisable within 60 days of April 3, 2025.                                                                   |
| (10) | Consists of (i) 31,462 shares of common stock.                                                                                        |
| (11) | Consists of the shares described in Notes (3) through (11) above, less                                                                
 the 1,957 shares of common stock held by Dr. Cipriani’s, whose employment with us terminated on October 3, 2024.                      |

| 7 |

<div align='center'>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</div>

The following describes all transactions since April
1, 2022, and all proposed transactions, in which we were or are to be a participant and the amount involved exceeds the lesser of $120,000
or one percent of the average of our total assets at year-end for the last two completed fiscal years, and in which any related person
had or will have a direct or indirect material interest. In making such decisions our Audit Committee considers and approves or disapproves
any related party transaction as defined under SEC Regulation Item 404, to the extent required by SEC regulations.

Separation Agreement with Former CEO

In connection with Charles J. Fisher, Jr. M.D.’s
resignation as the Company’s Chief Executive Officer, effective November 2023 (the “Separation Date”), in accordance
with the terms of his Executive Employment Agreement with the Company, dated as of October 30, 2020 (the “Fisher Employment Agreement”),
and pursuant to Dr. Fisher’s Separation Agreement with the Company, effective as of November 27, 2023 (the “Separation Agreement”),
the Company will provide Dr. Fisher with (1) cash severance equivalent to twelve months of Dr. Fisher’s base salary in effect as
of the Separation Date, subject to standard payroll deductions and withholdings, payable over the Company’s regular payroll schedule
over the twelve months following the Separation Date; (2) the accelerated vesting on fifty percent (50%) of the outstanding and unvested
equity awards held by Dr. Fisher that were subject to time-based vesting as of the Separation Date, which were deemed fully vested and
exercisable as of the Separation Date; and (3) reimbursement of COB